<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36927502</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000705</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000705</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We have developed a new conceptual model to characterise the signs and symptoms of SLE: the Type 1 and 2 SLE Model. Within the original model, Type 1 SLE consists of inflammatory manifestations like arthritis, nephritis and rashes; Type 2 SLE includes symptoms of fatigue, myalgia, mood disturbance and cognitive dysfunction. Through in-depth interviews, we explored how the Type 1 and 2 SLE Model fits within the lived experience of patients with SLE, with a focus on the connection between Type 1 and Type 2 SLE symptoms.</AbstractText><AbstractText Label="METHODS">Semistructured in-depth interviews were conducted among adult participants meeting 1997 American College of Rheumatology or Systemic Lupus International Collaborating Clinics criteria for SLE. Participants were purposefully selected for age, race, sex and nephritis history. All interviews were audio-recorded and transcribed. Data were analysed through episode profile and thematic analysis.</AbstractText><AbstractText Label="RESULTS">Through interviews with 42 patients with SLE, two patterns of Type 2 SLE emerged: Intermittent (n=18) and Persistent (n=24). Participants with Intermittent Type 2 SLE described feeling generally well when Type 1 is inactive; these participants were younger and had more internal SLE manifestations. Participants with Persistent Type 2 described always experiencing Type 2 symptoms despite inactive Type 1, although the severity may fluctuate. Participants with Persistent Type 2 SLE experienced traditional lupus symptoms of joint pain, hair loss and rash, but less often had severe organ system involvement.</AbstractText><AbstractText Label="CONCLUSIONS">By listening to the stories of our patients, we found two underlying patterns of Type 2 SLE: Intermittent Type 2 symptoms that resolve in synchrony with Type 1 inflammatory symptoms, and Persistent Type 2 symptoms that continue despite remission of Type 1 symptoms.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eudy</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-3107-5545</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA amanda.eudy@duke.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0001-5524-8642</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corneli</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenna</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maheswaranathan</LastName><ForeName>Mithu</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0866-0022</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisetsky</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Durham Veterans Affairs Medical Center, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Criscione-Schreiber</LastName><ForeName>Lisa G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doss</LastName><ForeName>Jayanth</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadun</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Kai</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8406-2932</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clowse</LastName><ForeName>Megan E B</ForeName><Initials>MEB</Initials><Identifier Source="ORCID">0000-0002-8579-3470</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 TR002554</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 MD012530</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012219" MajorTopicYN="Y">Rheumatology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009393" MajorTopicYN="Y">Nephritis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">qualitative research</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Competing interests: AME reports grant support from Exagen to her institution outside the submitted work. JLR reports grant support from Exagen to her institution outside the submitted work; consulting fees from Eli Lilly, Immunovant and Exagen. AC reports grant support from UCB to her institution outside the submitted work. DSP reports consulting fees from Immunovant and participation on a Data Safety Monitoring Board or Advisory Board for Bristol Myers Squibb. LGC-S reports grant support from GlaxoSmithKline to her institution outside the submitted work; honorarium from Pennsylvania State University and the American College of Rheumatology. JD reports grant support from Pfizer outside the submitted work. MEBC reports grant support from Exagen, UCB and GlaxoSmithKline to her institution outside the submitted work; consulting fees from UCB, AstraZeneca and GlaxoSmithKline outside the submitted work. KM, MM and RES have no relevant competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>8</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36927502</ArticleId><ArticleId IdType="pmc">PMC9362789</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000705</ArticleId><ArticleId IdType="pii">9/1/e000705</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jump RL, Robinson ME, Armstrong AE, et al. . Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 2005;32:1699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">16142863</ArticleId></ArticleIdList></Reference><Reference><Citation>Karol DE, Criscione-Schreiber LG, Lin M, et al. . Depressive symptoms and associated factors in systemic lupus erythematosus. Psychosomatics 2013;54:443&#x2013;50. 10.1016/j.psym.2012.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psym.2012.09.004</ArticleId><ArticleId IdType="pubmed">23274009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiani AN, Petri M. Quality-of-life measurements versus disease activity in systemic lupus erythematosus. Curr Rheumatol Rep 2010;12:250&#x2013;8. 10.1007/s11926-010-0114-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-010-0114-1</ArticleId><ArticleId IdType="pubmed">20586000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiani AN, Strand V, Fang H, et al. . Predictors of self-reported health-related quality of life in systemic lupus erythematosus. Rheumatology 2013;52:1651&#x2013;7. 10.1093/rheumatology/ket171</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket171</ArticleId><ArticleId IdType="pmc">PMC3741477</ArticleId><ArticleId IdType="pubmed">23681396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of rheumatology SLE neuropsychological battery. Arthritis Rheum 2006;55:628&#x2013;35. 10.1002/art.22101</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22101</ArticleId><ArticleId IdType="pubmed">16874786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriya B, Gladman DD, Iba&#xf1;ez D, et al. . Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008;59:181&#x2013;5. 10.1002/art.23339</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23339</ArticleId><ArticleId IdType="pubmed">18240183</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersson S, L&#xf6;vgren M, Eriksson LE, et al. . An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol 2012;41:383&#x2013;90. 10.3109/03009742.2012.677857</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2012.677857</ArticleId><ArticleId IdType="pubmed">22646821</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrente-Segarra V, Carbonell-Abell&#xf3; J, Castro-Oreiro S, et al. . Association between fibromyalgia and psychiatric disorders in systemic lupus erythematosus. Clin Exp Rheumatol 2010;28:S22&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21122268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence RC, Helmick CG, Arnett FC, et al. . Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778&#x2013;99. 10.1002/1529-0131(199805)41:5&amp;lt;778::AID-ART4&amp;gt;3.0.CO;2-V</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199805)41:5&amp;lt;778::AID-ART4&amp;gt;3.0.CO;2-V</ArticleId><ArticleId IdType="pubmed">9588729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F, Ross K, Anderson J, et al. . The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19&#x2013;28. 10.1002/art.1780380104</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780380104</ArticleId><ArticleId IdType="pubmed">7818567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009;61:822&#x2013;9. 10.1002/art.24519</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24519</ArticleId><ArticleId IdType="pmc">PMC2763591</ArticleId><ArticleId IdType="pubmed">19479699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler RC, McGonagle KA, Zhao S, et al. . Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8&#x2013;19. 10.1001/archpsyc.1994.03950010008002</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.1994.03950010008002</ArticleId><ArticleId IdType="pubmed">8279933</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi ST, Kang JI, Park I-H, et al. . Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage. Clin Exp Rheumatol 2012;30:665&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">22704691</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca R, Bernardes M, Terroso G, et al. . Silent burdens in disease: fatigue and depression in SLE. Autoimmune Dis 2014;2014:79072410.1155/2014/790724</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/790724</ArticleId><ArticleId IdType="pmc">PMC3926392</ArticleId><ArticleId IdType="pubmed">24592329</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterling K, Gallop K, Swinburn P, et al. . Patient-reported fatigue and its impact on patients with systemic lupus erythematosus. Lupus 2014;23:124&#x2013;32. 10.1177/0961203313511554</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313511554</ArticleId><ArticleId IdType="pubmed">24197552</ArticleId></ArticleIdList></Reference><Reference><Citation>Tench CM, McCurdie I, White PD, et al. . The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology 2000;39:1249&#x2013;54. 10.1093/rheumatology/39.11.1249</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/39.11.1249</ArticleId><ArticleId IdType="pubmed">11085805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS, Clowse MEB, Criscione-Schreiber LG, et al. . A novel system to categorize the symptoms of systemic lupus erythematosus. Arthritis Care Res 2019;71:735&#x2013;41. 10.1002/acr.23794</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23794</ArticleId><ArticleId IdType="pubmed">30354033</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand V, Berry P, Lin X, et al. . Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: six years of treatment. Arthritis Care Res 2019;71:829&#x2013;38. 10.1002/acr.23788</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23788</ArticleId><ArticleId IdType="pmc">PMC6593666</ArticleId><ArticleId IdType="pubmed">30320964</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand V, Levy RA, Cervera R, et al. . Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2014;73:838&#x2013;44. 10.1136/annrheumdis-2012-202865</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202865</ArticleId><ArticleId IdType="pmc">PMC3995218</ArticleId><ArticleId IdType="pubmed">23524886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:40. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Kim MY, Kalunian KC, et al. . Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550&#x2013;8. 10.1056/NEJMoa051135</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa051135</ArticleId><ArticleId IdType="pubmed">16354891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F, Clauw DJ, Fitzcharles MA. Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;2016:319&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">27916278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F, Walitt BT, Rasker JJ, et al. . The use of polysymptomatic distress categories in the evaluation of fibromyalgia (FM) and FM severity. J Rheumatol 2015;42:1494&#x2013;501. 10.3899/jrheum.141519</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.141519</ArticleId><ArticleId IdType="pmc">PMC4755344</ArticleId><ArticleId IdType="pubmed">26077414</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton M. Qualitative research. John Wiley &amp; Sons, Ltd, 2005.</Citation></Reference><Reference><Citation>Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods 2006;18:59&#x2013;82.</Citation></Reference><Reference><Citation>Saunders B, Sim J, Kingstone T, et al. . Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant 2018;52:1893&#x2013;907. 10.1007/s11135-017-0574-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11135-017-0574-8</ArticleId><ArticleId IdType="pmc">PMC5993836</ArticleId><ArticleId IdType="pubmed">29937585</ArticleId></ArticleIdList></Reference><Reference><Citation>Maietta R, Mihas P, Swartout K, et al. . Sort and sift, think and shift: let the data be your guide an applied approach to working with, learning from, and privileging qualitative data. TQR 2021;26:2045&#x2013;60. 10.46743/2160-3715/2021.5013</Citation><ArticleIdList><ArticleId IdType="doi">10.46743/2160-3715/2021.5013</ArticleId></ArticleIdList></Reference><Reference><Citation>Guest G, MacQueen KM, Namey EE. Applied thematic analysis. Sage Publications, 2012.</Citation></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D. European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;2019:1400&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan M, Harwood R, Sutton S, et al. . Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. Rheumatol Adv Pract 2020;4:rkaa006. 10.1093/rap/rkaa006</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkaa006</ArticleId><ArticleId IdType="pmc">PMC7197794</ArticleId><ArticleId IdType="pubmed">32373774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson W, Katz P, Daly R, et al. . Lupus flare activity from the patient perspective [abstract]. Arthritis Rheumatol 2018;70.</Citation></Reference><Reference><Citation>Carlucci P, Li J, Gold H. Patients enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms [abstract]. Arthritis Rheumatol 2021;73.</Citation></Reference><Reference><Citation>Rogers J, Clowse M, Criscione-Schreiber L. Lupus nephritis is associated with a reduced prevalence of fibromyalgia [abstract]. Arthritis Rheumatol 2020;72.</Citation></Reference><Reference><Citation>Johnson SR, Brinks R, Costenbader KH, et al. . Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Ann Rheum Dis 2020;79:1333&#x2013;9. 10.1136/annrheumdis-2020-217162</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217162</ArticleId><ArticleId IdType="pubmed">32816709</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio J, Krishfield S, Kyttaris VC. Application of the 2019 European League Against Rheumatism/American College of Rheumatology systemic lupus erythematosus classification criteria in clinical practice: a single center experience. Lupus 2020;29:421&#x2013;5. 10.1177/0961203320908939</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320908939</ArticleId><ArticleId IdType="pubmed">32098572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Pons-Estel GJ, Griffin R, et al. . Achievement of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Criteria for systemic lupus erythematosus and amount of damage accrual: results from a multiethnic multicenter cohort. Arthritis Care Res 2021;73:1038&#x2013;40. 10.1002/acr.24213</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24213</ArticleId><ArticleId IdType="pubmed">32293109</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>